PRKAR1B

PRKAR1B encodes the RIβ regulatory subunit of cAMP-dependent protein kinase (PKA), which homodimerizes and assembles with two catalytic (C) subunits to form the type I PKA holoenzyme, serving as a key mediator of cAMP-dependent signaling in neurons. Disease-associated missense variants exert two distinct pathogenic mechanisms: mutations such as L50R disrupt RIβ homodimerization, producing misfolded monomers that aggregate in an age- and cAMP-dependent manner, prevent holoenzyme assembly and AKAP anchoring, and cause aberrant nuclear translocation of the catalytic subunit with consequent hyperphosphorylation of neuronal intermediate filaments and altered gene expression (PMID:24722252, PMID:38743596, PMID:40244081), whereas variants such as A67V, A300T, R115K, and R335W increase RIβ–Cα binding affinity and reduce basal PKA activity, establishing that both gain and loss of RIβ–C interaction dysregulate PKA signaling (PMID:32895490, PMID:33833410, PMID:34195525). Mutations in PRKAR1B cause a neurodegenerative disorder characterized by neuronal RIβ-positive inclusions and a neurodevelopmental syndrome, linking disrupted PKA holoenzyme regulation directly to human neurological disease (PMID:24722252, PMID:33833410).

1. 2012 Low

   Alternative splicing of Prkar1b generates N-terminally distinct RIβ isoforms, raising the question of whether different isoforms engage distinct AKAP partners and thus diversify subcellular PKA signaling.

   Evidence RT-PCR and sequencing of mouse brain cDNA identified three splice variants with different N-terminal domains

   PMID:22446042

   Open questions at the time

   • AKAP-docking specificity of individual isoforms is inferred computationally but not tested biochemically
   • Tissue-specific expression levels of each isoform are not quantified
   • Functional relevance of each isoform in vivo is unknown
2. 2014 Medium

   The first disease-linked PRKAR1B mutation (L50R) demonstrated that RIβ is essential for proper AKAP anchoring and catalytic subunit localization in neurons, and that its disruption causes intermediate filament hyperphosphorylation and neuronal inclusion pathology.

   Evidence Exome sequencing of affected families, proteomics and biochemical binding assays, and immunohistochemistry of post-mortem brain tissue

   PMID:24722252

   Open questions at the time

   • Binding defects were inferred from co-immunoprecipitation without reconstituted purified proteins
   • Whether intermediate filament hyperphosphorylation is directly catalyzed by mislocalized C subunit was not shown
   • No animal model was available at this stage
3. 2020 Medium

   Identification of A67V and A300T variants revealed a second pathogenic mode — increased RIβ–Cα affinity with suppressed basal PKA activity — showing that both loosened and tightened regulatory-catalytic interactions are pathogenic.

   Evidence FRET-based interaction assay and PKA enzymatic activity measurement in co-transfected HEK293 cells; copy-number analysis in adrenal adenomas

   PMID:32895490

   Open questions at the time

   • FRET measurements were performed in a single cell system without purified-protein confirmation
   • Downstream phosphorylation substrates affected by reduced basal PKA activity not identified
   • Whether adrenal copy-number gains act through the same biochemical mechanism as missense variants is unresolved
4. 2021 Medium

   The R335W and R115K variants expanded the allelic series and confirmed that diverse PRKAR1B missense mutations converge on dysregulated PKA activity, firmly establishing PRKAR1B as a neurodevelopmental disease gene.

   Evidence PKA activity assays and FRET in transfected cells for R335W; FRET and enzymatic assays plus structural modeling for R115K

   PMID:33833410 PMID:34195525

   Open questions at the time

   • Structural basis for altered cAMP-binding cooperativity at domain A (R115K) relies on in silico prediction
   • Neurodevelopmental phenotype mechanism not dissected at the cellular level
   • No in vivo model for these specific variants
5. 2024 High

   A knock-in mouse model and human tissue studies established the molecular mechanism of L50R pathology: the mutation disrupts RIβ homodimerization, generating monomers that aggregate in a cAMP-accelerated and age-dependent manner, with catalytic subunit binding providing dose-dependent protection against aggregation.

   Evidence Biochemical dimerization and aggregation assays, Prkar1b-L50R knock-in mouse behavioral and histological analysis, human post-mortem brain immunohistochemistry, live cell culture experiments

   PMID:38743596

   Open questions at the time

   • Whether pharmacological enhancement of C-subunit binding can prevent aggregation therapeutically is untested
   • Whether non-L50R dimerization-domain mutations share the same aggregation mechanism is unknown
6. 2025 High

   Purified-protein biophysics revealed that L50R causes RIβ misfolding (not just dissociation), that the L50R:C heterodimer retains high affinity but loses cooperativity — requiring less cAMP for dissociation — and that the freed catalytic subunit translocates to the nucleus and alters gene expression, directly linking holoenzyme instability to transcriptional dysregulation.

   Evidence Circular dichroism spectroscopy and purified protein measurements; nuclear translocation assays in patient-derived cells; rescue by an engineered mutation reducing RIβ:C dissociation

   PMID:40244081

   Open questions at the time

   • Specific nuclear substrates and gene expression changes downstream of aberrant C-subunit translocation not catalogued
   • Structural basis of reduced cooperativity at atomic resolution not resolved
   • Whether reduced cooperativity is a general feature of other pathogenic RIβ variants is unknown

• Key unresolved questions include the identity of nuclear PKA substrates and transcriptional programs altered by mislocalized catalytic subunit, the structural basis for how different mutations produce opposing effects on RIβ–C affinity, and whether therapeutic stabilization of the RIβ homodimer or holoenzyme can prevent neuronal aggregation and disease.
• No phosphoproteomics of nuclear targets downstream of aberrant C-subunit translocation
• No high-resolution structure of full-length RIβ holoenzyme with or without disease mutations
• Therapeutic strategies targeting holoenzyme stability are unexplored